The use of in vitro kinetic models in the evaluation of beta-lactamase inhibitors.
D000658:Amoxicillin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001768:Blister / Q000378:metabolism; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D008962:Models, Theoretical; D010406:Penicillins / Q000493:pharmacokinetics*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects; D013982:Ticarcillin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D065093:beta-Lactamase Inhibitors
D002969:Clavulanic Acids; D010406:Penicillins; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D000658:Amoxicillin; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin